Published in final edited form as:

Mol Cell Neurosci. 2015 September ; 68: 73–81. doi:10.1016/j.mcn.2015.04.003.

Rapid transient isoform-specific neuregulin1 transcription in motor neurons is regulated by neurotrophic factors and axon-target interactions

Jiajing Wang¹, Abdelkrim Hmadcha^{1,2}, Vaagn Zakarian¹, Fei Song^{1,3,*}, and Jeffrey A. Loeb^{1,3,*}

¹The Center for Molecular Medicine & Genetics, Wayne State University School of Medicine, Detroit, MI 48201, USA

²Department of Stem Cells, CABIMER–Fundación Progreso y Salud, Sevilla 41092, Spain

³Department of Neurology and Rehabilitation, The University of Illinois at Chicago, Chicago, IL 60612, USA

Abstract

The neuregulins (NRGs) are a family of alternatively spliced factors that play important roles in nervous system development and disease. In motor neurons, NRG1 expression is regulated by activity and neurotrophic factors, however, little is known about what controls isoform-specific transcription. Here we show that NRG1 expression in the chick embryo increases in motor neurons that have extended their axons and that limb bud ablation before motor axon outgrowth prevents this induction, suggesting a trophic role from the developing limb. Consistently, *NRG1* induction after limb bud ablation can be rescued by adding back the neurotrophic factors BDNF and GDNF. Mechanistically, BDNF induces a rapid and transient increase in type I and type III *NRG1* mRNAs that peak at 4 h in rat embryonic ventral spinal cord cultures. Blocking MAPK or PI3K signaling or blocking transcription with Actinomycin D blocks BDNF induced *NRG1* gene induction. BDNF had no effect on mRNA degradation, suggesting that transcriptional activation rather than message stability is important. Furthermore, BDNF activates a reporter construct that includes 700bp upstream of the type I *NRG1* start site. Protein synthesis is also required for type I *NRG1* mRNA transcription as cycloheximide produced a super-induction of type I, but not type III *NRG1* mRNA, possibly through a mechanism involving sustained activation of MAPK and PI3K. These results reveal the existence of highly responsive, transient transcriptional regulatory mechanisms that differentially modulate *NRG1* isoform expression as a function of extracellular and intracellular signaling cascades and mediated by neurotrophic factors and axon-target interactions.

*Co-Corresponding authors: Dr. Jeffrey A. Loeb and Dr. Fei Song, Department of Neurology and Rehabilitation, University of Illinois at Chicago, NPI North Bldg., Room 657, M/C 796, 912 S. Wood Street, Chicago, IL 60612, Tel: 312-996-1757, jaloeb@uic.edu; feisong@uic.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Neuregulin1; Neurotrophic factor; Brain-derived neurotrophic factor; Transcriptional regulation; Motor neuron

Introduction

Proper function of the nervous system requires orchestrated communication between neurons and many other cell types. Some of this communication occurs through the regulated release of growth and differentiation factors such as NRG1. Alternative splicing produces both membrane-bound and secreted forms of NRG1 (Falls, 2003, Mei and Xiong, 2008) that have been shown to be important in many aspects of nervous system and cardiac development and linked to peripheral nerve injury, heart failure, schizophrenia, multiple sclerosis, and cancer. All NRG1 splice forms share an EGF-like domain necessary and sufficient to activate hetero- and homo-dimeric combinations of ErbB2, ErbB3, and ErbB4 receptors (Esper et al., 2006). NRG1-ErbB signaling has been implicated in regulating Schwann cell survival, growth, differentiation, and myelination (Nave and Salzer, 2006, Ma et al., 2011), for modulating the expression of acetylcholine receptors at the neuromuscular junction (NMJ) (Li et al., 2004, Schmidt et al., 2011, Ngo et al., 2012), and inducing muscle spindle differentiation (Hippenmeyer et al., 2002).

Much of how different NRG1 isoforms are spatially segregated is due to alternative splicing (Falls, 2003, Mei and Xiong, 2008). Most are produced as transmembrane precursors processed through proteolytic cleavage (Kalinowski et al., 2010, La Marca et al., 2011, Luo et al., 2011). Cleavage of type I and type II NRG1 isoforms sheds their extracellular domains producing biologically active soluble forms with an N-terminal, heparin-binding domain (HBD) used for selective cellular targeting to heparan sulfate proteoglycan (HSPG) rich cell surfaces (Loeb et al., 1999, Pankonin et al., 2005, Ma et al., 2009, Ma et al., 2011). Type III NRG1 isoforms have a hydrophobic cysteine-rich domain (CRD) keeping them membrane-tethered and enabling signaling through cell-cell contact (Wang et al., 2001).

The regulatory mechanisms that produce various NRG1 isoforms are not well understood, however, in schizophrenia transcriptional regulation of specific isoforms have been implicated (Stefansson et al., 2002). We have shown that NRG1 expression can be mediated by neurotrophic factors, providing a positive feedback loop with nearby cells (Esper et al., 2006, Ma et al., 2011). At the NMJ, muscle targets produce neurotrophic factors, including BDNF and GDNF (Henderson et al., 1993, Henderson et al., 1994) that induce *NRG1* mRNA and protein expression (Loeb and Fischbach, 1997) and promote the rapid release of soluble NRG1 from sensory and motor neuron axons in a dose- and time-dependent manner (Esper and Loeb, 2004, 2009). Here, we provide evidence that target-derived neurotrophic factors promote both type I and type III *NRG1* expression in developing chick motor neurons *in ovo* and in mammalian cultured motor neurons. Mechanistically, the effects of BDNF on *NRG1* transcription are rapid and transient and require both intracellular signaling cascades and ongoing protein synthesis. These studies are important for understanding the

bidirectional communication between motor neurons and muscle targets during development and in pathological conditions.

Results

Axon-target interactions regulate *NRG1* mRNA expression

We have previously observed that *NRG1* protein and mRNA increases in spinal motor neurons following their birth and migration towards the lateral portion of the developing spinal cord in chicken embryos (Loeb et al., 1999). Using the homeodomain motor neuron marker *Islet-1/2*, *NRG1* protein expression is seen to be highest in those motor neurons that have completed their migration and have extended their axons into the surrounding mesoderm (Fig 1). These observations suggest that factors provided to outgrowing axons promote *NRG1* expression. In order to test for this, unilateral hind limb bud ablation was performed *in ovo* at E2.5, prior to axon outgrowth into the limb bud (Tosney and Landmesser, 1985) (Fig. 2A, 2B). With this model, motor axons spiral into a ball in the absence of a target to innervate. After limb bud ablation, but before the period of programmed cell death at E6, *NRG1* mRNA levels did not increase on the ablated side as they do on the control side in the lateral portion of the lateral motor column (LMC_L) that normally innervate the dorsal limb bud (Fig. 2C, 2D). The weakly positive *Islet-1/2* marker is used to label the LMC_L , which shows no reduction of motor neuron numbers even after ablation (data not shown). This marker was used for double labeling radioactive *in situ* experiments in Fig. 2C showing decreased mRNA levels in the LMC_L on the side of the limb ablation (Fig. 2D). Consistently, quantitative RT-PCR (qPCR) using isoform-specific primers showed reduced expression of both type I/II (HBD) and type III (CRD) *NRG1*, suggesting that axon target interactions are important to induce both of these major *NRG1* isoform classes (Fig. 2E).

Neurotrophic factors can restore *NRG1* mRNA expression in motor neurons lacking targets

A lack of neurotrophic support is one possible explanation for the failure of *NRG1* mRNA induction following limb bud ablation. Developing muscles provide a range of neurotrophic factors that support motor neuron survival and neuromuscular junction development (Levi-Montalcini and Calissano, 1979, Henderson et al., 1993, Henderson et al., 1994). These factors have distinct expression profiles at different developmental stages. Therefore, we asked whether exogenous BDNF, GDNF, or NGF could rescue *NRG1* mRNA expression after unilateral limb ablation. This was determined by measuring the ratio of *NRG1* mRNA levels in the LMC_L on the operated versus control sides of the spinal cord at E6 with or without addition of these factors at E4 (Fig. 3A). While both BDNF and GDNF maintained normal *NRG1* mRNA levels in motor neurons that lack targets, NGF failed to rescue expression (Fig. 3A, 3B). This is consistent with their known presence during development and known actions, since both BDNF and GDNF receptors have been shown to be expressed in developing motor neurons (Henderson et al., 1993, Homma et al., 2003), and muscle- and Schwann cell-derived BDNF and GDNF have been shown to be potent survival factors for motor neurons (Yan et al., 1992, Henderson et al., 1994), whereas NGF and its receptors have little effect on motor system development (Funakoshi et al., 1993, Ip et al., 2001).

Type I and type III *NRG1* mRNAs are rapidly and transiently upregulated by neurotrophic factors in mammalian motor neuron cultures

To address further the mechanism by which neurotrophic factors regulate *NRG1* mRNA expression, we utilized an established, rat embryonic ventral spinal cord culture system in which we have previously shown rapid (within 4 hours) effects of BDNF and GDNF on *NRG1* mRNA levels (Loeb et al., 1999). Using isoform-specific qPCR, we found type I *NRG1* mRNA was induced by both BDNF and GDNF, whereas type III *NRG1* mRNA was induced to a smaller extent only by BDNF (Fig. 4A). No significant change was observed for type II *NRG1* mRNA. Type I *NRG1* mRNA peaked at 4 h, but declined rapidly by 6 h, and then returned to baseline 8 h after BDNF application, whereas type III *NRG1* was also induced at 4 h, it did not return to baseline until 8 h (Fig. 4B). This difference in kinetics was seen consistently for both type I and type III *NRG1* isoforms (n=3~6). The demonstration that both type I and type III, but not type II, *NRG1* mRNA levels are rapidly and transiently induced with BDNF stimulation, but with distinct temporal profiles, suggest both common and unique regulatory mechanisms.

TrkB, MAPK and PI3K signaling are required for BDNF-induced *NRG1* expression

To explore the signaling pathways involved in the regulation of type I and type III *NRG1* mRNA by BDNF, we pretreated cultured cells with specific inhibitors prior to BDNF application. BDNF binds to either the TrkB tyrosine kinase or the low-affinity nerve growth factor receptor p75 and is known to lead to the activation of mitogen-activated protein kinase (MAPK), phosphatidylinositol-3 kinase (PI3K) and phospholipase C- γ (PLC- γ) (Segal, 2003). Inhibition of TrkB activation by K-252a blocked type I and type III *NRG1* mRNA induction by BDNF at 4 h (Fig. 5A, 5B). Furthermore, inhibition of either MAPK by the MEK inhibitor PD98059 or U0126, or PI3K by LY294002 or Wortmannin, blocked *NRG1* mRNA induction by BDNF (Fig. 5C, 5D). These findings suggest that TrkB, MAPK, and PI3K signaling pathways are all involved in type I and type III *NRG1* mRNA induction.

BDNF-induced *NRG1* induction requires new transcription

The increase in mRNA levels could have resulted from either an increased rate of transcription, mRNA stabilization, or both. To distinguish between these, we measured mRNA levels after BDNF-treatment in the presence or absence of the transcription inhibitor Actinomycin D (ActD). Pretreatment with ActD for 30 min completely prevented *NRG1* mRNA induction by BDNF, demonstrating that ongoing gene transcription is necessary for BDNF-evoked type I and type III *NRG1* mRNA upregulation (Fig. 6A). To address whether the turnover rate of *NRG1* mRNA is altered by BDNF, cultures were treated with ActD in the presence and absence of BDNF and mRNA levels were measured as a function of time. Interestingly, type I *NRG1* mRNA was relatively short-lived, with half-life of about 1h, whereas type III *NRG1* mRNA was more stable, with twice the half-life of about 2h (Fig. 6B). Since the presence or absence of BDNF had no clear effects on the turnover ratio of either type I or type III *NRG1* mRNA, these findings suggest the most important effect of BDNF is on transcriptional activation rather than on mRNA stability.

Given the importance of transcription, we next investigated the effects of BDNF on the 5' cis-elements upstream to type I and type III *NRG1* transcripts in rat embryonic ventral spinal

cord cultures. Firefly luciferase constructs were prepared containing the 5' promoter regions flanking the transcription start sites for rat type I (−649 to +5) and type III (−1343 to +31) *NRG1* (Fig. 7A). Each of these constructs was co-electroporated with the control vector pRL-TK in order to normalize the *NRG1* induced luciferase activity with Rellina luciferase activity. After 24h, BDNF induced the type I promoter-driven luciferase. While the type-III promoter luciferase activity was induced with the same trend, it did not reach statistical significance (Fig. 7B). These findings suggest that cis-acting elements contribute to type I *NRG1* transcription induced by BDNF.

Protein synthesis is required to maintain type I *NRG1* mRNA transcription

The transient nature of *NRG1* mRNA induction by BDNF could have important biological implications. Exactly how *NRG1* transcription is precisely shut off after 4–6 hours after BDNF exposure was assessed using the protein synthesis inhibitor cycloheximide (CHX) in rat embryonic ventral spinal cord cultures with and without BDNF treatment. Remarkably, CHX treatment prevented the downregulation of type I *NRG1* after 4 h of BDNF treatment, and instead led to an almost 10-fold 'superinduction' (Fig. 8A). Even in the absence of BDNF treatment, CHX produced a steady increase of type I *NRG1* mRNA. In contrast, CHX had no effect on type III *NRG1* expression (Fig. 8B).

This superinduction of type I *NRG1* could either be due to increased gene transcription or reduced degradation. However, the kinetics of type I *NRG1* mRNA stability was unchanged in the presence of CHX, suggesting that the effect on protein synthesis is also related to increased transcription (Fig. 8C). Given the requirement for both MAPK and PI3K signaling from Figure 5, we asked whether CHX affected the activation of MAPK and PI3K signaling after BDNF stimulation in the presence and absence of CHX (Fig. 8D). In contrast to a rapid, transient induction of pERK, p38, and pAKT (peaked at 30 min), BDNF treatment in the presence of CHX produced a more sustained, long-term activation of all of these signaling intermediates with the greatest effect on pERK. These results suggest that protein synthesis is required to downregulate long-term signaling effects of BDNF, with the greatest effect on MAPK signaling. These results also show additional differences in the transcriptional regulatory mechanisms between type I and type III *NRG1* forms, since there was no effect of blocking protein synthesis on type III forms.

Discussion

A reciprocal axon-target feedback loop mediated by *NRG1* and neurotrophic factors

Both neuron-derived *NRG1* and target-derived neurotrophic factors have been implicated to be important in neuromuscular system development. The functions of these mediators rely not only on the dynamic distribution of their receptors, but also on the temporal and spatial expression profile of the ligands. This diversity allows a multi-directional crosstalk between cells that can be both temporally and spatially restricted, depending on the need biologically. Here we have focused on the extracellular signaling mechanisms that underlie axon-target interactions in the developing spinal cord and limb bud. We show that axon-target interactions promote *NRG1* expression in spinal motor neurons and that this effect can be replicated by target-derived neurotrophic factors, such as BDNF and GDNF. *In vitro*, we

show that BDNF induces a rapid, yet transient upregulation of *NRG1* mRNA that works through new transcription and is mediated by TrkB-MAPK and TrkB-PI3k signaling pathways as well as by distinct 5' regulatory cis-elements. Both MAPK and PI3k signaling pathways have been shown to be activated by GDNF in different circumstances as well (Airaksinen and Saarma, 2002). The rapid (4 h) nature of the induction may be important to increase transcription in only those axons that make proper contact with their target. The transient nature of the induction (sharply falls after 4 h) requires protein synthesis and is associated with a rapid shut down of the TrkB signaling cascades. Biologically, this could be important to limit *NRG1* expression in axons that do not have sustained contact with their destined targets. For secreted (type I) forms of *NRG1*, in addition to these transcriptional mechanisms, we have previously shown that BDNF can work postrtranslationally to promote the local release of *NRG1* from axons via a mechanism that requires protein kinase C- δ (Esper and Loeb, 2004, 2009).

In addition to survival, target-derived neurotrophic factors have been implicated in supporting motor neuron function by eliciting transcriptional and translational changes (Chowdary et al., 2012). In the present study, deprivation of target-derived neurotrophic factors by unilateral removal of developing limb buds prior to the period of programmed cell death did not lead to programmed cell death, but did lead to changes in two out of the three major spliced forms of *NRG1*. How neurotrophic factor signaling in axons is relayed to motor neuron nuclei is not entirely clear, but has been extensively studied (Segal, 2003, Zweifel et al., 2005). Neurotrophic factor signaling pathways can also differ depending on the cellular localization of their receptors (Chowdary et al., 2012). For example, retrograde NGF-TrkA signaling on axons results in Erk5 activation to mediate NGF pro-survival signaling in dorsal root ganglion cells, while activation of TrkA in the cell bodies of these neurons uses Erk1/2 activation (Watson et al., 2001). It has been reported that Akt can be phosphorylated by PDK1 at threonine 308 (Thr308) in the activation loop of the kinase and mTORC2 complex at serine 473 (Ser473) in the hydrophobic motif in different circumstances (Vanhaesebroeck and Alessi, 2000, Sarbassov et al., 2005). Thus, future studies could explore the activation dynamics of different phosphorylation sites within Akt signaling pathway upon BDNF. Another level of complexity is that there are a number of seemingly redundant neurotrophic factors that can converge on common pathways. Here, we found that both BDNF and GDNF could rescue *NRG1* expression after limb bud ablation while NGF failed. While this is consistent with the expression of profiles of their receptors, the crosstalk and downstream differences in signaling pathways from each factor adds additional complexity to this communication 'language.' We chose to focus on BDNF because of a lack of specific GDNF-Ret inhibitors, and because the effect of BDNF was much greater than GDNF *in vitro*.

The complexity of *NRG1* gene structure and isoform-specific expression

The human *NRG1* gene is one of the longest and complex genes in the genome that is located on chromosome 8p12 and spans over 1M bp. Recent studies from the ENCODE project have shown regions within this gene that have DNase hypersensitivity implicating the presence of cis-regulatory elements (Rosenbloom et al., 2013). One of the highest DNase-sensitive clusters is located -1-3kb to the transcription start site of type I *NRG1*.

Consistently, this enrichment region has high density of H3K27Ac and H3K4Me3 histones and transcriptional factor binding sites, determined by ChIP-seq analysis. All of these markers suggest that the ~4–5 kb DNA fragment might be important regulatory regions for type I *NRG1* expression (Rosenbloom et al., 2013). Consistently, we showed that BDNF can induce transcription of a portion of this cis-element. It would be worthwhile to investigate if this region, especially the region within the first intron that has not been analyzed before (Frensing et al., 2008, Liu et al., 2011), is responsible for the binding of regulatory factors induced by neurotrophic factors signaling.

Alternative splicing produces a daunting array of NRG1 proteins that have been actively investigated over the years (Falls, 2003). In this study we focused on 3 major protein forms that have been shown to have important differences in how and where they signal. For example, type I and type II forms both produce secreted proteins that have heparin-binding domains, but type II has an additional N-terminal Kringle domain of unclear function. Despite the similarity, we found that BDNF had no effect on type II *NRG1* transcription, but affected both type I and type III. Type III NRG1 isoforms are unique in that they have a second membrane-spanning region thought to activate its receptors through direct cell-cell interactions (Wang et al., 2001). While BDNF induced both type I and type III *NRG1* forms by 4 h, there were differences in both the magnitude of the effect and the kinetics. Type III *NRG1* induction by BDNF was lower, but stayed turned on longer (over 6 h) and was more slowly degraded than type I *NRG1*. In addition, the BDNF effect on the 5' cis-regulatory type III elements was less strong than for type I *NRG1* at different time points (data not shown), suggesting the requirement of additional regulatory regions or additional mechanisms. A functional interaction between these two promoters also cannot be ruled out. Finally, the mechanism requiring protein synthesis that shuts off type I *NRG1* expression does not occur for type III forms as cycloheximide had no effect on type III *NRG1*. Taken together, each splice form has transcriptional and postranscriptional regulatory machinery that can fine-tune its expression leading to a dynamic, spatially and temporally unique pattern of NRG1 signaling in motor neurons. The distinct regulatory patterns of neurotrophic factors exert their differential effects on different isoforms of NRG1 provide a level of precision and complexity. This is because modes of function of the isoforms are complementary, with diffusion and binding to HSPGs for type I versus cell-cell contact for type III; and because their respective targets can be different.

Wider roles for NRG1-BDNF reciprocal signaling in the nervous system

NRG1, neurotrophic factors, and their respective receptor systems have all been shown to play critical roles in many aspects of nervous system development and in disease. For example, both signaling pathways are involved in long-term potentiation (LTP) in the hippocampus, however, studies have shown opposite effect with BDNF facilitating and NRG1 suppressing LTP (Patterson et al., 1996, Huang et al., 2000, Chen et al., 2010). The expression of BDNF and NRG1 are tightly regulated by neuronal activity both at the neuromuscular junction (Loeb et al., 2002) and in the CNS (Flavell and Greenberg, 2008, Liu et al., 2011). However, the link between these two signaling pathways in the CNS has not been investigated. Thus, similar regulatory machinery might exist in the CNS as we have found peripherally here. Models of epilepsy have also been used to show activity

dependence. Activity-dependent transcription of BDNF has been shown to promote epileptogenesis (He et al., 2004) and *NRG1* mRNA increases in the hippocampus after a single electrical stimulation-induced seizure (Tan et al., 2012). Finally, NRG1 has recently been implicated in models of chronic pain after nerve injury (Calvo et al., 2010) and in both human tissues and an animal model of ALS through activation of microglia (Song et al., 2012). Understanding extracellular signaling through neurotrophic factors as well as the intracellular signaling cascades that promote NRG1 expression could therefore be used to develop therapeutic targets for these disorders.

Materials and Methods

Reagents

The following reagents were purchased from Sigma-Aldrich: K-252a (K1639, dissolved in DMSO), PD98059 (P215, dissolved in DMSO), LY294002 (L9908, dissolved in DMSO) and Wortmannin (W1628, dissolved in DMSO), Actinomycin D (A1410, dissolved in DMSO), Cycloheximide solution (C4859). U0126 (#9903, dissolved in DMSO) was obtained from Cell Signaling Technology.

Chick eggs, unilateral limb ablation and *in ovo* treatment

Fertilized chicken eggs were obtained from Michigan State University Poultry Farms and incubated in a Kuhl rocking incubator at 50% humidity. Limb buds were removed unilaterally on E2.5 and embryos were returned to the incubator until indicated times as previously described (Tosney and Landmesser, 1985). Any unsuccessful ablations, that did not yield an absent limb, were not used for the study. Recombinant BDNF, GDNF (Amgen), or NGF (Life Technologies) was added as described previously (Loeb et al., 2002, Ma et al., 2009). In brief, 1 µg/embryo/day of BDNF, GDNF or NGF were prepared in saline containing 0.2% BSA, respectively and added onto the chorioallantoic membrane for two consecutive days. Embryos were collected at indicated times and processed for total RNA, or *in situ* hybridization combined with immunofluorescence staining as described below. Staging of chick embryos was determined according to Hamburger-Hamilton (HH) stage series (Hamburger and Hamilton, 1951): E3 (stage 18–19); E4 (stage 23–24); E5 (stage 26–27); E6 (stage 28–29).

Immunofluorescence staining and *in situ* hybridization

Embryos were fixed in 4% paraformaldehyde in PBS at 4°C overnight, washed in PBS, equilibrated in 30% sucrose, and sectioned into 20 µm sections. Neuregulin was labeled using 1310 antibodies against the proNRG1 precursor cytoplasmic tail (Loeb et al., 1999). RT-97 (1:50) and Islet-1/2 (1:50) were obtained from Developmental Studies Hybridoma Bank, University of Iowa, to label neurofilament and spinal cord motor neurons, respectively. Sections were incubated with antibodies in blocking solution (10% normal goat serum, 0.1% Triton X-100 in PBS) overnight at 4°C, followed by incubation with the corresponding goat anti-mouse or anti-rabbit Alexa Fluor antibodies (1:500; Life Technologies) for visualization. Radioactive *in situ* hybridization was performed using ³⁵S-labeled RNA probes as previously described (Beaumont et al., 2012). In brief, sense and antisense ³⁵S-labeled RNA probes were generated from linearized full-length chicken

proARIA cDNA clones by *in vitro* transcription. Probes were purified on NuClean R50 Sephadex columns (Shelton Scientific). Tissues were hybridized at 52°C overnight, followed by washing, and dehydrated in ethanol. Slides were then dipped in photographic emulsion (Kodak NTB), dried, and exposed for 7 days or longer at 4°C.

Imaging and quantitative analysis

Digital images were captured using a Nikon Eclipse E600 microscope with a Princeton Instruments Micromax cooled CCD digital camera. Signal intensities were quantified using MetaMorph image analysis software (Molecular Devices). Spinal cord lateral motor columns (lateral portions) were defined using a double labeling immunofluorescence and radioactive *in situ* hybridization protocol by first labeling the sections with Islet-1/2, showing a reduced signal in these regions (Jessell, 2000). *In situ* hybridizations were performed on the same sections. Regions of interest (ROIs) were selected based on weaker Islet-1/2 signal at the most lateral part of the ventral spinal cord. *In situ* signal intensity was measured for each ROI and the ratios of operated/control sides were calculated by dividing average grey value of operated side by the counterpart of control side within the same section.

Primary rat embryonic ventral spinal cord cultures

Primary rat embryonic ventral spinal cord cultures were prepared as described previously (Loeb and Fischbach, 1997). Briefly, ventral spinal cords were dissected from embryos from timed pregnant Sprague Dawley rats (Harlan) using the ventral two-third of the spinal cords of embryonic day 15 (E15) rat embryos. Cells were plated on laminin and poly-D-lysine-coated 24-well plates at density of 200,000 cells/cm² in Leibovitz's L-15 Glutamax Medium supplemented with N-2 supplement, MEM vitamin solution, penicillin/streptomycin (Life Technologies), 6 mM NaHCO₃, 6 µg/ml chick E11 pectoral muscle extract, and 54 µg/ml imidazole. Cultures were maintained at 37°C with 5% CO₂. At day *in vitro* 3 (DIV3), cultures were treated with BDNF, GDNF, or NT-3 for indicated time periods. In some experiments, inhibitors were added 30 min before the neurotrophic factors. At the end of treatments, cells were washed with cold PBS and subjected to total RNA or protein extraction.

RNA isolation and qPCR

5- to 6-somite segments of lumbar spinal cords were harvested from unilateral limb ablated chick embryos at E6 and then separated for RNA extraction. Total RNA from both tissue and cell cultures were isolated using RNeasy mini kit (Qiagen). Equal amounts of total RNAs were reverse transcribed using oligo(dT) by Superscript First-Strand Synthesis System (Life Technologies). Chick IG-NRG1 and CRD-NRG1 transcripts were detected as previously described (Ma et al., 2011). Rat type I and type II *NRG1* were measured by Rn00580917_m1 and Rn01482172_m1, respectively; type III *NRG1* were detected by: forward primer, 5'-TCCTAAACTTTCCACATCGACATC; reverse primer, 5'-TCTCATAAAGTGCGCGGAG; and taqman probe, 6FAM-ACGACTGGGACCAGC. Rat GAPDH was detected by Rn99999916_s1 for normalization (Life Technologies). Message

levels of *NRG1* isoforms were normalized to GAPDH. qPCR data were collected from at least three biological replicates, and $\Delta\Delta C_t$ was used for calculations.

Protein isolation and immunoblotting

Total protein from rat embryonic ventral spinal cord cultures was extracted using RIPA lysis and extraction buffer containing 25 mM Tris, pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, and Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific). Equal amounts of protein samples were loaded for immunoblotting using antibodies from Cell Signaling Technology at the following dilutions: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (1:1000, #4370), p44/42 MAPK (Erk1/2) (1:1000, #4695); Phospho-p38 MAPK (Thr180/Tyr182) (1:1000, #4511), p38 MAPK (1:1000, #8690); Phospho-Akt (Ser473) (1:1000, #4060), Akt (pan) (1:1000, #4685). SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) was used for signal detection. Blots were first probed with antibodies against phospho-proteins and then stripped for reprobing.

Dual luciferase reporter assay

5' flanking regions of type I and type III *NRG1*s were amplified by PCR from rat genomic DNA using the forward primer, 5'-TGCTTAGGAAGAAGCTAGAGTGAGT, and the reverse primer, 5'-TCAGACATCTCGCCGAAGATGA for type I; forward primer, 5'-TAAGAGTCCTGTGAGTGAAC, and reverse primer, 5'-ATGTCTGGGGAATAAATCTC for type III. They were subcloned into pGL3B vector, upstream to the firefly luciferase gene, and verified by sequencing. Dissociated cells from rat embryonic ventral spinal cord were cotransfected by electroporation (Neon Transfection System, Life Technologies) with type I promoter-Luc or type III promoter-Luc together with thymidine kinase promoter-Renilla luciferase reporter plasmid (pRL-TK) at ratio of 50:1. 12 h after transfection, cells were treated with BDNF as indicated for 24 h before lysis. Luciferase activities were assayed using Dual-Luciferase Reporter Assay System (Promega) by a Fluoroskan Ascent microplate luminometer (Thermo Scientific). Firefly luciferase activity was normalized by Renilla luciferase activity to eliminate sample variation.

Statistical analysis

A paired two-tailed Student *t*-test was used to calculate differences between two groups. Statistical differences for multiple group comparisons were calculated using a one-way ANOVA followed by Dunnett *post hoc* test. For comparisons of multiple groups with different treatments, a two-way ANOVA followed by Bonferroni *post hoc* test by comparison to control was used. Normalized values were averaged and reported as the mean $\pm$ SEM of at least three independent experiments. Statistical significance is presented as * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, ns not-significant.

Acknowledgements

This work was supported by NIH Grant RO1 NS059947 and the Hiller Amyotrophic Lateral Sclerosis Center.

References

- Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. *Nature reviews Neuroscience*. 2002; 3:383–394. [PubMed: 11988777]
- Beaumont TL, Yao B, Shah A, Kapatos G, Loeb JA. Layer-specific CREB target gene induction in human neocortical epilepsy. *J Neurosci*. 2012; 32:14389–14401. [PubMed: 23055509]
- Calvo M, Zhu N, Tsantoulas C, Ma Z, Grist J, Loeb JA, Bennett DL. Neuregulin-ErbB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury. *J Neurosci*. 2010; 30:5437–5450. [PubMed: 20392965]
- Chen YJ, Zhang M, Yin DM, Wen L, Ting A, Wang P, Lu YS, Zhu XH, Li SJ, Wu CY, Wang XM, Lai C, Xiong WC, Mei L, Gao TM. ErbB4 in parvalbumin-positive interneurons is critical for neuregulin 1 regulation of long-term potentiation. *Proc Natl Acad Sci U S A*. 2010; 107:21818–21823. [PubMed: 21106764]
- Chowdary PD, Che DL, Cui B. Neurotrophin signaling via long-distance axonal transport. *Annual review of physical chemistry*. 2012; 63:571–594.
- Esper RM, Loeb JA. Rapid axoglial signaling mediated by neuregulin and neurotrophic factors. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2004; 24:6218–6227. [PubMed: 15240814]
- Esper RM, Loeb JA. Neurotrophins induce neuregulin release through protein kinase Cdelta activation. *The Journal of biological chemistry*. 2009; 284:26251–26260. [PubMed: 19648576]
- Esper RM, Pankonin MS, Loeb JA. Neuregulins: versatile growth and differentiation factors in nervous system development and human disease. *Brain research reviews*. 2006; 51:161–175. [PubMed: 16412517]
- Falls DL. Neuregulins: functions, forms, and signaling strategies. *Exp Cell Res*. 2003; 284:14–30. [PubMed: 12648463]
- Flavell SW, Greenberg ME. Signaling mechanisms linking neuronal activity to gene expression and plasticity of the nervous system. *Annu Rev Neurosci*. 2008; 31:563–590. [PubMed: 18558867]
- Frensing T, Kaltschmidt C, Schmitt-John T. Characterization of a neuregulin-1 gene promoter: positive regulation of type I isoforms by NF-kappaB. *Biochim Biophys Acta*. 2008; 1779:139–144. [PubMed: 18082154]
- Funakoshi H, Frisen J, Barbany G, Timmusk T, Zachrisson O, Verge VM, Persson H. Differential expression of mRNAs for neurotrophins and their receptors after axotomy of the sciatic nerve. *J Cell Biol*. 1993; 123:455–465. [PubMed: 8408225]
- Hamburger V, Hamilton HL. A series of normal stages in the development of the chick embryo. *J Morph*. 1951; 88:49–92. [PubMed: 24539719]
- He XP, Kotloski R, Nef S, Luikart BW, Parada LF, McNamara JO. Conditional deletion of TrkB but not BDNF prevents epileptogenesis in the kindling model. *Neuron*. 2004; 43:31–42. [PubMed: 15233915]
- Henderson CE, Camu W, Mettling C, Gouin A, Poulsen K, Karihaloo M, Rullamas J, Evans T, McMahon SB, Armanini MP, et al. Neurotrophins promote motor neuron survival and are present in embryonic limb bud. *Nature*. 1993; 363:266–270. [PubMed: 8487864]
- Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, Simmons L, Moffet B, Vandlen RA, Simpson LC, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. *Science*. 1994; 266:1062–1064. [PubMed: 7973664]
- Hippenmeyer S, Shneider NA, Birchmeier C, Burden SJ, Jessell TM, Arber S. A role for neuregulin1 signaling in muscle spindle differentiation. *Neuron*. 2002; 36:1035–1049. [PubMed: 12495620]
- Homma S, Yaginuma H, Vinsant S, Seino M, Kawata M, Gould T, Shimada T, Kobayashi N, Oppenheim RW. Differential expression of the GDNF family receptors RET and GFRalpha1, 2, and 4 in subsets of motoneurons: a relationship between motoneuron birthdate and receptor expression. *The Journal of comparative neurology*. 2003; 456:245–259. [PubMed: 12528189]
- Huang YZ, Won S, Ali DW, Wang Q, Tanowitz M, Du QS, Pelkey KA, Yang DJ, Xiong WC, Salter MW, Mei L. Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses. *Neuron*. 2000; 26:443–455. [PubMed: 10839362]

- Ip FC, Cheung J, Ip NY. The expression profiles of neurotrophins and their receptors in rat and chicken tissues during development. *Neurosci Lett*. 2001; 301:107–110. [PubMed: 11248434]
- Jessell TM. Neuronal specification in the spinal cord: inductive signals and transcriptional codes. *Nature reviews Genetics*. 2000; 1:20–29.
- Kalinowski A, Plowes NJ, Huang Q, Berdejo-Izquierdo C, Russell RR, Russell KS. Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells. *FASEB J*. 2010; 24:2567–2575. [PubMed: 20215529]
- La Marca R, Cerri F, Horiuchi K, Bachi A, Feltri ML, Wrabetz L, Blobel CP, Quattrini A, Salzer JL, Taveggia C. TACE (ADAM17) inhibits Schwann cell myelination. *Nat Neurosci*. 2011; 14:857–865. [PubMed: 21666671]
- Levi-Montalcini R, Calissano P. The nerve-growth factor. *Scientific American*. 1979; 240:68–77. [PubMed: 472707]
- Li Q, Esper RM, Loeb JA. Synergistic effects of neuregulin and agrin on muscle acetylcholine receptor expression. *Mol Cell Neurosci*. 2004; 26:558–569. [PubMed: 15276157]
- Liu X, Bates R, Yin DM, Shen C, Wang F, Su N, Kirov SA, Luo Y, Wang JZ, Xiong WC, Mei L. Specific regulation of NRG1 isoform expression by neuronal activity. *J Neurosci*. 2011; 31:8491–8501. [PubMed: 21653853]
- Loeb JA, Fischbach GD. Neurotrophic factors increase neuregulin expression in embryonic ventral spinal cord neurons. *Journal of Neuroscience*. 1997; 17:1416–1424. [PubMed: 9006983]
- Loeb JA, Hmadcha A, Fischbach GD, Land SJ, Zakarian VL. Neuregulin expression at neuromuscular synapses is modulated by synaptic activity and neurotrophic factors. *J Neurosci*. 2002; 22:2206–2214. [PubMed: 11896160]
- Loeb JA, Khurana TS, Robbins JT, Yee AG, Fischbach GD. Expression patterns of transmembrane and released forms of neuregulin during spinal cord and neuromuscular synapse development. *Development*. 1999; 126:781–791. [PubMed: 9895325]
- Luo X, Prior M, He W, Hu X, Tang X, Shen W, Yadav S, Kiryu-Seo S, Miller R, Trapp BD, Yan R. Cleavage of neuregulin-1 by BACE1 or ADAM10 protein produces differential effects on myelination. *J Biol Chem*. 2011; 286:23967–23974. [PubMed: 21576249]
- Ma Z, Li Q, An H, Pankonin MS, Wang J, Loeb JA. Targeting HER signaling with neuregulin's heparin-binding domain. *J Biol Chem*. 2009
- Ma Z, Wang J, Song F, Loeb JA. Critical period of axoglial signaling between neuregulin-1 and brain-derived neurotrophic factor required for early Schwann cell survival and differentiation. *J Neurosci*. 2011; 31:9630–9640. [PubMed: 21715628]
- Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. *Nat Rev Neurosci*. 2008; 9:437–452. [PubMed: 18478032]
- Nave KA, Salzer JL. Axonal regulation of myelination by neuregulin 1. *Curr Opin Neurobiol*. 2006; 16:492–500. [PubMed: 16962312]
- Ngo ST, Cole RN, Sunn N, Phillips WD, Noakes PG. Neuregulin-1 potentiates agrin-induced acetylcholine receptor clustering through muscle-specific kinase phosphorylation. *J Cell Sci*. 2012; 125:1531–1543. [PubMed: 22328506]
- Pankonin MS, Gallagher JT, Loeb JA. Specific structural features of heparan sulfate proteoglycans potentiate neuregulin-1 signaling. *J Biol Chem*. 2005; 280:383–388. [PubMed: 15528194]
- Patterson SL, Abel T, Deuel TA, Martin KC, Rose JC, Kandel ER. Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. *Neuron*. 1996; 16:1137–1145. [PubMed: 8663990]
- Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM, Wong MC, Maddren M, Fang R, Heitner SG, Lee BT, Barber GP, Harte RA, Diekhans M, Long JC, Wilder SP, Zweig AS, Karolchik D, Kuhn RM, Haussler D, Kent WJ. ENCODE data in the UCSC Genome Browser: year 5 update. *Nucleic acids research*. 2013; 41:D56–D63. [PubMed: 23193274]
- Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science*. 2005; 307:1098–1101. [PubMed: 15718470]
- Schmidt N, Akaaboune M, Gajendran N, Martinez-Pena y Valenzuela I, Wakefield S, Thurnheer R, Brenner HR. Neuregulin/ErbB regulate neuromuscular junction development by phosphorylation of alpha-dystrobrevin. *J Cell Biol*. 2011; 195:1171–1184. [PubMed: 22184199]

- Segal RA. Selectivity in neurotrophin signaling: theme and variations. *Annu Rev Neurosci.* 2003; 26:299–330. [PubMed: 12598680]
- Song F, Chiang P, Wang J, Ravits J, Loeb JA. Aberrant neuregulin 1 signaling in amyotrophic lateral sclerosis. *Journal of neuropathology and experimental neurology.* 2012; 71:104–115. [PubMed: 22249457]
- Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K. Neuregulin 1 and susceptibility to schizophrenia. *Am J Hum Genet.* 2002; 71:877–892. [PubMed: 12145742]
- Tan GH, Liu YY, Hu XL, Yin DM, Mei L, Xiong ZQ. Neuregulin 1 represses limbic epileptogenesis through ErbB4 in parvalbumin-expressing interneurons. *Nat Neurosci.* 2012; 15:258–266. [PubMed: 22158510]
- Tosney KW, Landmesser LT. Development of the major pathways for neurite outgrowth in the chick hindlimb. *Dev Biol.* 1985; 109:193–214. [PubMed: 2985457]
- Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. *The Biochemical journal.* 2000; 346(Pt 3):561–576. [PubMed: 10698680]
- Wang JY, Miller SJ, Falls DL. The N-terminal region of neuregulin isoforms determines the accumulation of cell surface and released neuregulin ectodomain. *J Biol Chem.* 2001; 276:2841–2851. [PubMed: 11042203]
- Watson FL, Heerssen HM, Bhattacharyya A, Klesse L, Lin MZ, Segal RA. Neurotrophins use the Erk5 pathway to mediate a retrograde survival response. *Nat Neurosci.* 2001; 4:981–988. [PubMed: 11544482]
- Yan Q, Elliott J, Snider WD. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. *Nature.* 1992; 360:753–755. [PubMed: 1281520]
- Zweifel LS, Kuruvilla R, Ginty DD. Functions and mechanisms of retrograde neurotrophin signalling. *Nat Rev Neurosci.* 2005; 6:615–625. [PubMed: 16062170]

Highlights

- Axon-target interactions regulate NRG1 mRNA expression during early development.
- Neurotrophic factors restore NRG1 mRNA expression in motor neurons lacking targets.
- Type I and III NRG1 mRNAs are upregulated by neurotrophic factors.
- TrkB, MAPK and PI3K signaling are required for BDNF-induced NRG1 expression.
- BDNF-induced NRG1 induction requires new transcription and protein synthesis.

Figure 1. NRG1 expression is maximal in motor neurons that have extended their axons
(A) Stage 18 embryonic chicken spinal cord was double-labeled with antibodies against NRG1 (green) and the motor neuron marker Islet-1/2 (red). Motor neurons that had extended their axons in the lateral spinal cord had the highest level of NRG1 protein expression. Higher power views are shown in (B).

Figure 2. Motor neurons that fail to contact their targets express lower NRG1 mRNA levels
 (A) Removal of the apical ectodermal ridge at E2.5 results in a unilateral limbless chicken embryo at E6. (B) Sections through the lumbar level show motor axons (RT-97, red) expressing NRG1 (1310, green) rolled into a ball (arrow), while contralateral axons innervate the limb normally. (C) *NRG1* mRNA levels were quantified using a double-labeling with immunofluorescence using islet-1/2 antibodies followed by radioactive *in situ* hybridization with a pan-*NRG1* probe. *In situ* hybridization signals were quantified from the LMC_L (ROI determined by weaker Islet-1/2 immunoreactivity in the most lateral part of the

ventral horn) and the ratio of *NRG1* mRNA expression on the operated/control side for each embryo was determined from E4–E6. (D) Limb bud ablation led to reduced *NRG1* levels the LMC_L at E5 and E6 (n=3 each stage). (E) In order to determine which *NRG1* isoforms were responsible for this reduction, control and ablated sides of the ventral lumbar spinal cord were isolated and HBD-NRG1 (type I/II) and CRD-NRG1 (type III) were quantified qPCR (n=10) after normalization to GAPDH for each animal. Both of these showed reduced mRNA levels on the ablated side. * $p < 0.05$, paired two-tailed Student *t*-test.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 3. NRG1 expression can be rescued by BDNF or GDNF after limb bud ablation
 (A) Representative images are shown of *in situ* hybridizations from the ventral spinal cords of limb-bud ablated chick embryostreated with Saline, BDNF, GDNF, or NGF using a pan-NRG1 probe. (B) Quantitative analysis using the ratio of *NRG1* in operated/control sides showed that BDNF and GDNF, but not NGF, rescued the decrease of *NRG1* mRNA on the ablated side. Data are reported as the mean $\pm$ SEM of $n=10, 17, 3, 5$, for Control, BDNF, GDNF, NGF, respectively, * $p<0.05$, ** $p<0.01$, one-way ANOVA followed by Dunnett *post hoc* test by comparison to control.

Figure 4. Differential regulation of NRG1 isoform mRNA levels by neurotrophic factors in rat embryonic ventral spinal cord cultures

(A) Disassociated E15 rat embryonic ventral spinal cords were cultured for three days and then treated with and without BDNF (100 ng/ml) or GDNF (100 ng/ml) for 4 h. BDNF and GDNF induced type I greater than type III, but not type II *NRG1* mRNA using isoform-specific qPCR. (B) A time course revealed that BDNF (100 ng/ml) induces type I *NRG1* mRNA maximally and transiently at 4 h. Type III is induced less at 4 h, but stays up longer than type I. Type II was unaffected by BDNF. Data reported are the mean $\pm$ SEM of three to

six independent experiments. * $p < 0.05$, *** $p < 0.001$, one-way ANOVA followed by Dunnett *post hoc* test by comparison to the control group (A), and 0h (B) for each isoform.

Figure 5. Trk receptor, MEK, and PI3K inhibitors block the effects of BDNF on NRG1 mRNA
 Rat embryonic ventral spinal cord cultures were exposed to K-252a (200 nM) (A, B) or PD98059 (10 μ M), U0126 (10 μ M), LY294002 (50 μ M), or Wortmannin (200 nM) (C, D) for 30 min prior to adding BDNF (100 ng/ml) for 4 h. The inhibitor pretreatment resulted in the abrogation of BDNF induction on both type I and type III *NRG1* compared to the diluents alone (no inhibitor). Data are reported as the mean $\pm$ SEM of at least three independent experiments, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, ns not-significant, two-way ANOVA followed by Bonferroni *post hoc* test by comparison to control.

Figure 6. BDNF promotes transcription but has no effect on mRNA stability

(A) Rat embryonic ventral spinal cords were treated with or without actinomycin D (ActD, 2 μ g/ml) for 30 minutes before BDNF (100 ng/ml) stimulation, and harvested at 4h. (B) A time course of *NRG1* decay with or without BDNF/ActD shows that BDNF does not change the rate of mRNA degradation rate for both type I and type III isoforms. Decay curves were fitted to a single-phase decay curve to calculate a $t_{1/2}$ =62 min ($R^2 = 0.93$) for type I with ActD and $t_{1/2}$ =67 min ($R^2 = 0.92$) for ActD + BDNF. In contrast, type III *NRG1* had a

$t_{1/2}=120$ min ($R^2 = 0.92$) for ActD and $t_{1/2}=111$ min ($R^2 = 0.85$) for ActD + BDNF treatment. Data are reported as the mean $\pm$ SEM of at least three independent experiments.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 7. The 5'-flanking region of type I *NRG1* is sufficient for BDNF induction of transcription (A) 5' promoter regions for type I and type III *NRG1* were cloned into a luciferase reporter plasmid as indicated. (B) Dissociated rat embryonic ventral spinal cords were electroporated with either each construct together with the pRL-TK control vector. 12h after electroporation, cells were treated with or without BDNF (100 ng/ml) for 24h before luciferase activity was measured. BDNF treatment induced the type I promoter-driven luciferase activity significantly, whereas there was only a non-significant increase using the type III promoter. Transcriptional activities were shown by fold change compared to control,

after normalization for transfection efficiency by the activity of renilla luciferase. Data are reported as the mean $\pm$ SEM of at least six biological replicates, ** $p < 0.01$, paired two-tailed Student t -test.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 8. Protein synthesis is required for the downregulating NRG1 mRNA after BDNF-induced stimulation

(A) Rat embryonic ventral spinal cord cultures were pretreated with or without cycloheximide (CHX, 20 μ g/ml) for 30 minutes before BDNF (100 ng/ml) stimulation. type I *NRG1* mRNA levels were elevated significantly by CHX alone and super-induced with both CHX and BDNF. (B) CHX had no clear effect on type III *NRG1* expression. (C) While CHX alone led to increased mRNA levels, CHX + ActD with or without BDNF had no effect on the rate of decay of type I *NRG1* mRNA. Data are reported as the mean $\pm$ SEM of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, two-way ANOVA followed by Bonferroni *post hoc* test by comparison to 0h. (D) CHX prevented the normal reduction in ERK, p38 and AKT signaling after BDNF treatment of rat embryonic ventral spinal cord cultures.